

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

YONGHE

雍禾医疗

Yonghe Medical Group Co., Ltd.

雍禾醫療集團有限公司

(a company incorporated in the Cayman Islands with limited liability)

(Stock Code: 2279)

CHANGE OF DIRECTORS AND MEMBER OF NOMINATION COMMITTEE

The Board is pleased to announce the following changes to the Board:

- (1) Mr. ZHAI Feng has tendered his resignation as a non-executive Director with effect from the conclusion of the AGM;
- (2) Ms. WANG Jiping has tendered her resignation as an independent non-executive Director and a member of the Nomination Committee with effect from the conclusion of the AGM;
- (3) Ms. HAN Zhimei has been proposed to be appointed as an executive Director, subject to the Shareholders' approval at the AGM;
- (4) Ms. LIANG Jihong has been proposed to be appointed as an independent non-executive Director, subject to the Shareholders' approval at the AGM; and
- (5) Mr. LI Xiaopei has been proposed to be appointed as a member of the Nomination Committee with effect from the conclusion of the AGM.

The board (the “**Board**”) of directors (“**Directors**”) of Yonghe Medical Group Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) announces the followings changes of Directors and member of the nomination committee of the Company (the “**Nomination Committee**”).

RESIGNATION OF DIRECTORS

The Board announces that on June 7, 2022, (i) Mr. ZHAI Feng tendered his resignation as a non-executive Director due to his other career commitment; and (ii) Ms. WANG Jiping tendered her resignation as an independent non-executive Director due to her other career commitment, each with effect from the conclusion of the Company's annual general meeting to be held on June 28, 2022 (the "AGM").

Each of Mr. ZHAI Feng and Ms. WANG Jiping has confirmed that he/she has no disagreement with the Board and there are no other matters relating to his/her resignation that need to be brought to the attention of the shareholders of the Company (the "Shareholders") or The Stock Exchange of Hong Kong Limited (the "Stock Exchange").

The Board would like to take this opportunity to express its sincere gratitude to Mr. ZHAI Feng and Ms. WANG Jiping for their contribution to the Company during their term of office.

APPOINTMENT OF DIRECTORS

The Board is pleased to announce that on June 7, 2022, (i) Ms. HAN Zhimei (韓志梅) ("Ms. Han") has been proposed to be appointed as an executive Director; and (ii) Ms. LIANG Jihong (梁繼紅) ("Ms. Liang") has been proposed to be appointed as an independent non-executive Director, each subject to the Shareholders' approval at the AGM.

The biographical details of Ms. Han and Ms. Liang are set out below:

Ms. Han, aged 45, has been the finance director of the Group since March 20, 2017. For further details of Ms. Han's background, please refer to the section headed "Director and Senior Management" of the Company's 2021 annual report published on April 27, 2022.

Subject to the Shareholders' approval of her appointment at the AGM, Ms. Han will enter into an appointment letter with the Company for a term of three years commencing from the effective date of her appointment for her services to the Company subject to retirement by rotation and re-election at least once every three years, in accordance with the articles of association of the Company and the Corporate Governance Code contained in Appendix 14 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules"). Ms. Han will not receive any fees from the Company for her positions as an executive Director. The remuneration for Ms. Han's position as finance director of the Group will be determined by the Company with reference to the Company's remuneration policy and taken into account, among other factors, her qualification and experience, responsibilities undertaken, contribution to the Group and the prevailing market level of remuneration of similar positions.

As at the date of this announcement and within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "SFO"), Ms. Han is the sole shareholder of Shanghai Zhizhen Technology Company Limited (上海致臻科技有限公司) which is the general partner of Shanghai Zhixin Technology Partnership (Limited Partnership) (上海致歆科技合夥企業(有限合夥)) ("Shanghai Zhixin"). Shanghai Zhixin holds 100% equity interest in Zhirui Technology Holdings Limited (致睿科技控股有限公司), the employee incentive platform for the employees of the Group, which holds 2.28% of the issued share capital of the Company.

Save as disclosed above, as at the date of this announcement, Ms. Han has confirmed that she does not hold (i) any other position with the Company or other members of the Group; (ii) any directorship in any other public companies with securities of which are listed on any securities market in Hong Kong or overseas in the last three years; and (iii) any other major appointments and professional qualifications.

Save as disclosed above, as at the date of this announcement, Ms. Han has confirmed that (i) she does not have any relationship with any Director, senior management or substantial shareholder or controlling shareholder of the Company, or any interest in the shares of the Company within the meaning of Part XV of the SFO; and (ii) there is no other information that is required to be disclosed pursuant to any of the requirements under paragraphs (h) to (v) of Rule 13.51(2) of the Listing Rules nor are there other matters that need to be brought to the attention of the Shareholders or the Stock Exchange relating to Ms. Han's appointment.

Ms. Liang, aged 49, has extensive experience in the financial and investment industry. Ms. Liang served in various positions, including chief financial officer and director, within the group of 36Kr Holdings Inc., a NASDAQ listed company (NASDAQ stock code: KRKR), from November 2014 to March 2021. Prior to that, Ms. Liang served as a financial director at Yeepay Inc., an e-payment service provider based in China, from July 2013 to November 2014, and as a financial director at Tujia.com, a Chinese lodging-service sharing and booking platform, from February 2012 to September 2012, respectively. Prior to that, Ms. Liang served as a senior financial manager at the Beijing branch of Ctrip.com, an online ticket and hotel booking platform based in China, from July 2011 to September 2012, and as a financial manager at the Beijing branch of Mangocity.com, an online ticket and hotel booking platform based in China, from February 2006 to July 2011, respectively.

Ms. Liang completed the FMBA program run by Cheung Kong Graduate School of Business in October 2021. Ms. Liang received her master's degree in software engineering from Beihang University (北京航空航天大学) in June 2016 and bachelor's degree in statistics from Capital University of Economics and Business (首都經濟貿易大學) in June 1995. Ms. Liang was admitted as a Certified Public Accountant by the Chinese Institute of Certified Public Accountants in January 2005.

Subject to the Shareholders' approval of her appointment at the AGM, Ms. Liang will enter into an appointment letter with the Company for a term of three years commencing from the effective date of her appointment for her services to the Company subject to retirement by rotation and re-election at least once every three years, in accordance with the articles of association of the Company and the Corporate Governance Code contained in Appendix 14 to the Listing Rules. According to the terms of Ms. Liang's appointment, Ms. Liang is entitled to a director's fee of HKD200,000 per annum, and Ms. Liang is entitled to the reimbursement of all reasonable out-of-pocket expenses incurred in relation to the discharge of her duties in connection with the business of the Company. The director's fee was recommended by the remuneration committee of the Company with reference to her duties and responsibilities with the Company, the Company's remuneration policy and the prevailing market conditions.

Save as disclosed above, as at the date of this announcement, Ms. Liang has confirmed that she does not hold (i) any other position with the Company or other members of the Group; (ii) any directorship in any other public companies with securities of which are listed on any securities market in Hong Kong or overseas in the last three years; and (iii) any other major appointments and professional qualifications.

Save as disclosed above, as at the date of this announcement, Ms. Liang has confirmed that (i) she does not have any relationship with any Director, senior management or substantial shareholder or controlling shareholder of the Company, or any interest in the shares of the Company within the meaning of Part XV of the SFO; and (ii) there is no other information that is required to be disclosed pursuant to any of the requirements under paragraphs (h) to (v) of Rule 13.51(2) of the Listing Rules nor are there other matters that need to be brought to the attention of the Shareholders or the Stock Exchange relating to Ms. Liang's appointment.

CHANGE OF MEMBER OF NOMINATION COMMITTEE

The Board further announces that on June 7, 2022, (i) Ms. WANG Jiping has tendered her resignation as a member of the Nomination Committee; and (ii) Mr. LI Xiaopei has been resolved to be appointed as a member of the Nomination Committee, each with effect from the conclusion of the AGM.

By Order of the Board
Yonghe Medical Group Co., Ltd.
ZHANG Yu
Chairman of the Board

Hong Kong, June 7, 2022

As at the date of this announcement, the executive directors of the Company are Mr. ZHANG Yu, Mr. ZHANG Hui, the non-executive directors of the Company are Mr. ZHAI Feng and Mr. GENG Jiaqi, and the independent non-executive directors of the Company are Ms. WANG Jiping, Mr. CHAN Peng Kuan and Mr. LI Xiaopei.